TY - JOUR
T1 - Clearance of Hepatitis C Virus (HCV) Is Associated With Improved Outcomes in HCV-Associated Lymphoma
AU - Desai, Sanjal H.
AU - Baez-Sosa, Valentina
AU - Hameed, Rumaisa
AU - Al-Shbool, Ghassan
AU - Fernandez, Stephen
AU - Vakiti, Anusha
AU - Stingo, Facundo
AU - Adhikari, Tripti
AU - Paku, Emily
AU - Malkovska, Vera
AU - Fishbein, Dawn
N1 - Publisher Copyright:
© 2020 Elsevier Inc.
PY - 2021/2
Y1 - 2021/2
N2 - Background: Improved hepatitis C virus (HCV) clearance due to directly acting antiviral agents has led to remarkably improved outcomes of indolent HCV-associated non-Hodgkin lymphoma (NHL). The impact of directly acting antivirals on the outcomes of aggressive NHL is still under investigation. Characteristics of HCV-associated NHL in black patients are not well characterized. We report outcomes of HCV-associated NHL compared to their HCV-negative counterparts in a predominantly black population. Patients and Methods: Patients with lymphoma between January 2007 and December 2017 were retrospectively studied. Depending on presence or absence of HCV RNA, patients were grouped into HCV positive (HCV+) and HCV negative (HCV−) cohorts. Depending on virologic clearance (VC), HCV+ were classified into HCV+ with VC and HCV+ without VC. Overall response rate (ORR), complete response, overall survival (OS), and progression-free survival (PFS) of HCV+ patients with and without VC were compared to HCV− patients. Results: Of 397 patients with lymphoma, 40 had HCV. Black comprised 90% of HCV+ patients. Diffuse large B-cell lymphoma was most frequent (47%) in the HCV+ group. HCV+ patients without VC had significantly worse OS and PFS compared to HCV− patients. There were no differences in ORR, complete response, PFS, and OS of HCV+ patients with VC and HCV− patients. These results were consistent in subgroups of diffuse large B-cell lymphoma and aggressive lymphoma. Conclusion: HCV clearance is positively associated with lymphoma outcomes in black patients. Patients who clear HCV have noninferior outcomes to HCV− patients, while those who fail to clear HCV have significantly worse outcomes. We report outcomes of hepatitis C virus (HCV)-associated lymphoma compared to HCV-negative counterparts in a predominantly black population. HCV-negative patients without virologic clearance (VC) had significantly worse survival compared to HCV-negative patients. There were no differences in response rates and survival of HCV-positive patients with VC and HCV-negative patients. These results were consistent in subgroups of diffuse large B-cell lymphoma and aggressive lymphoma.
AB - Background: Improved hepatitis C virus (HCV) clearance due to directly acting antiviral agents has led to remarkably improved outcomes of indolent HCV-associated non-Hodgkin lymphoma (NHL). The impact of directly acting antivirals on the outcomes of aggressive NHL is still under investigation. Characteristics of HCV-associated NHL in black patients are not well characterized. We report outcomes of HCV-associated NHL compared to their HCV-negative counterparts in a predominantly black population. Patients and Methods: Patients with lymphoma between January 2007 and December 2017 were retrospectively studied. Depending on presence or absence of HCV RNA, patients were grouped into HCV positive (HCV+) and HCV negative (HCV−) cohorts. Depending on virologic clearance (VC), HCV+ were classified into HCV+ with VC and HCV+ without VC. Overall response rate (ORR), complete response, overall survival (OS), and progression-free survival (PFS) of HCV+ patients with and without VC were compared to HCV− patients. Results: Of 397 patients with lymphoma, 40 had HCV. Black comprised 90% of HCV+ patients. Diffuse large B-cell lymphoma was most frequent (47%) in the HCV+ group. HCV+ patients without VC had significantly worse OS and PFS compared to HCV− patients. There were no differences in ORR, complete response, PFS, and OS of HCV+ patients with VC and HCV− patients. These results were consistent in subgroups of diffuse large B-cell lymphoma and aggressive lymphoma. Conclusion: HCV clearance is positively associated with lymphoma outcomes in black patients. Patients who clear HCV have noninferior outcomes to HCV− patients, while those who fail to clear HCV have significantly worse outcomes. We report outcomes of hepatitis C virus (HCV)-associated lymphoma compared to HCV-negative counterparts in a predominantly black population. HCV-negative patients without virologic clearance (VC) had significantly worse survival compared to HCV-negative patients. There were no differences in response rates and survival of HCV-positive patients with VC and HCV-negative patients. These results were consistent in subgroups of diffuse large B-cell lymphoma and aggressive lymphoma.
KW - Black
KW - Chemoimmunotherapy
KW - Diffuse large B cell lymphoma
KW - Directly acting antiviral therapy
KW - Non-Hodgkin's lymphoma
UR - http://www.scopus.com/inward/record.url?scp=85094813509&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85094813509&partnerID=8YFLogxK
U2 - 10.1016/j.clml.2020.09.011
DO - 10.1016/j.clml.2020.09.011
M3 - Article
C2 - 33132102
AN - SCOPUS:85094813509
SN - 2152-2650
VL - 21
SP - e185-e193
JO - Clinical Lymphoma, Myeloma and Leukemia
JF - Clinical Lymphoma, Myeloma and Leukemia
IS - 2
ER -